Plans for appropriate follow-up should be made. The patient should be reassessed after a trial of monotherapy with an intranasal corticosteroid or oral antihistamine (ideally within 5-7 days).[3]Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. J Allergy Clin Immunol. 2020 Oct;146(4):721-67.
https://www.jacionline.org/article/S0091-6749(20)31023-X/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/32707227?tool=bestpractice.com
When symptoms improve, decreasing or discontinuing treatment may be considered.[3]Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. J Allergy Clin Immunol. 2020 Oct;146(4):721-67.
https://www.jacionline.org/article/S0091-6749(20)31023-X/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/32707227?tool=bestpractice.com
[67]Bousquet J, Schünemann HJ, Togias A, et al. Next-generation Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020 Jan;145(1):70-80.e3.
https://www.jacionline.org/article/S0091-6749(19)31187-X/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/31627910?tool=bestpractice.com